Higher Rates of Dose Optimisation for Infliximab Responders in Ulcerative Colitis than in Crohn's disease.
Sarah O'Donnell, Joanne M Stempak, A Hillary Steinhart, Mark S Silverberg
Author Information
Sarah O'Donnell: Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital IBD Group, Toronto, ON, Canada Division of Gastroenterology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
Joanne M Stempak: Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital IBD Group, Toronto, ON, Canada Division of Gastroenterology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
A Hillary Steinhart: Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital IBD Group, Toronto, ON, Canada Division of Gastroenterology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
Mark S Silverberg: Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital IBD Group, Toronto, ON, Canada Division of Gastroenterology, Department of Medicine, University of Toronto, Toronto, ON, Canada msilverberg@mtsinai.on.ca.
BACKGROUND: Studies have demonstrated the benefit of dose optimisation in the setting of secondary loss of response to infliximab in inflammatory bowel disease. AIM: The aim of our study was to retrospectively investigate the rates of dose optimisation in an inflammatory bowel disease cohort receiving maintenance infliximab therapy to determine if there are different rates of dose optimisation between CD and UC cases and what impact this has on the durability of treatment effect. METHODS: Cases receiving infliximab for treatment of IBD between January 2008 and February 2014 were identified from an infusion centre database. Cases receiving ≥ 4 infusions were included in the study. Details of infusion dosing and timing were obtained. A dose increase from 5mg/kg to 10mg/kg or a reduction in the dosing interval was considered a dose optimisation. RESULTS: A total of 412 cases were included in the study; 52.7% required at least one dose optimisation. Dose optimisation was more common in UC than in CD cases [67.2% vs 46.3%, p = 0.00006]. The median time to dose optimisation was 7 months (95% confidence interval [CI] 4.8-9.2) for UC cases and 27 months [95% CI 7.3-46.7] for CD cases, p = 0.00003. CONCLUSIONS: Here we have shown that dose optimisation is required more frequently in UC than in CD, with a significantly shorter time to dose optimisation for UC cases than CD cases. The majority of cases responding to induction therapy with infliximab will have a sustained response to therapy, but over 50% will require a dose optimisation during their treatment.
